Literature DB >> 24548099

Osteopontin splice variant as a potential marker for metastatic disease in pancreatic adenocarcinoma.

Ali A Siddiqui1, Elizabeth Jones, Darren Andrade, Apeksha Shah, Thomas E Kowalski, David E Loren, Galina Chipitsyna, Hwyda A Arafat.   

Abstract

BACKGROUND AND AIM: Osteopontin (OPN) is a phosphoprotein that activates pathways that induce cancer cell survival and metastasis. Our aim was to examine the expression pattern of OPN splice variants a, b, and c in fine-needle aspirates and to determine their correlation with stage-adjusted pancreatic ductal adenocarcinoma (PDA) survival.
METHODS: Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) was performed in patients with solid pancreatic masses. The tissue was collected and analyzed for the expression of OPN isoforms by reverse transcription-polymerase chain reaction. Survival curves of stages and overexpression of OPN splice variants (a, b, c) were estimated according to the Kaplan-Meier and the log-rank test.
RESULTS: EUS-FNA was performed in 46 patients with solid pancreatic lesions (40 PDA and 6 chronic pancreatitis). OPNa was highly expressed in 39/40 (98%), OPNb in 24/40 (60%), while OPNc was present in 10/40 (25%) of PDA samples. The median survival was lower in patients whose fine-needle aspiration (FNA) samples expressed OPNb than those without (406 days vs 749 days, P = 0.049). There was no significant difference in survival in patients with OPNc. Cox proportional hazard model demonstrated that OPNb expression had a trend toward decrease overall survival (P = 0.06), with these patients having a hazard of death three times higher than those without. OPNc was found to significantly correlate with metastatic disease (P = 0.009) in PDA patients.
CONCLUSIONS: Our data show for the first time that in FNA samples, there is a strong association between OPNc and presence of metastasis in PDA, and OPNb and poor survival.
© 2014 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  cytology; fine-needle aspirates; osteopontin; pancreatic cancer

Mesh:

Substances:

Year:  2014        PMID: 24548099      PMCID: PMC4465289          DOI: 10.1111/jgh.12561

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  28 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

Review 2.  The alpha(v)beta3 integrin, NF-kappaB, osteoprotegerin endothelial cell survival pathway. Potential role in angiogenesis.

Authors:  Marta Scatena; Cecilia Giachelli
Journal:  Trends Cardiovasc Med       Date:  2002-02       Impact factor: 6.677

Review 3.  Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival.

Authors:  D T Denhardt; M Noda; A W O'Regan; D Pavlin; J S Berman
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

4.  Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling.

Authors:  Deepak Agrawal; Tingan Chen; Rosalyn Irby; John Quackenbush; Ann F Chambers; Marianna Szabo; Alan Cantor; Domenico Coppola; Timothy J Yeatman
Journal:  J Natl Cancer Inst       Date:  2002-04-03       Impact factor: 13.506

5.  Site-directed mutagenesis of the arginine-glycine-aspartic acid sequence in osteopontin destroys cell adhesion and migration functions.

Authors:  J W Xuan; C Hota; Y Shigeyama; J A D'Errico; M J Somerman; A F Chambers
Journal:  J Cell Biochem       Date:  1995-04       Impact factor: 4.429

6.  Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma.

Authors:  Jens Koopmann; Neal S Fedarko; Alka Jain; Anirban Maitra; Christine Iacobuzio-Donahue; Ayman Rahman; Ralph H Hruban; Charles J Yeo; Michael Goggins
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2004-03       Impact factor: 4.254

Review 7.  Osteopontin: a protein with diverse functions.

Authors:  D T Denhardt; X Guo
Journal:  FASEB J       Date:  1993-12       Impact factor: 5.191

8.  Secreted phosphoprotein mRNA is induced during multi-stage carcinogenesis in mouse skin and correlates with the metastatic potential of murine fibroblasts.

Authors:  A M Craig; G T Bowden; A F Chambers; M A Spearman; A H Greenberg; J A Wright; M McLeod; D T Denhardt
Journal:  Int J Cancer       Date:  1990-07-15       Impact factor: 7.396

9.  cDNA cloning, mRNA distribution and heterogeneity, chromosomal location, and RFLP analysis of human osteopontin (OPN).

Authors:  M F Young; J M Kerr; J D Termine; U M Wewer; M G Wang; O W McBride; L W Fisher
Journal:  Genomics       Date:  1990-08       Impact factor: 5.736

Review 10.  Molecular and cellular basis of genetic resistance to bacterial infection: the role of the early T-lymphocyte activation-1/osteopontin gene.

Authors:  R Patarca; R A Saavedra; H Cantor
Journal:  Crit Rev Immunol       Date:  1993       Impact factor: 2.214

View more
  5 in total

1.  Osteopontin (OPN) isoforms, diabetes, obesity, and cancer; what is one got to do with the other? A new role for OPN.

Authors:  Konrad Sarosiek; Elizabeth Jones; Galina Chipitsyna; Mazhar Al-Zoubi; Christopher Kang; Shivam Saxena; Ankit V Gandhi; Jocelyn Sendiky; Charles J Yeo; Hwyda A Arafat
Journal:  J Gastrointest Surg       Date:  2015-01-13       Impact factor: 3.452

2.  Overexpressing TNF-alpha in pancreatic ductal adenocarcinoma cells and fibroblasts modifies cell survival and reduces fatty acid synthesis via downregulation of sterol regulatory element binding protein-1 and activation of acetyl CoA carboxylase.

Authors:  Mazhar Al-Zoubi; Galina Chipitsyna; Shivam Saxena; Konrad Sarosiek; Ankit Gandhi; Christopher Y Kang; Daniel Relles; Jocelyn Andrelsendecki; Terry Hyslop; Charles J Yeo; Hwyda A Arafat
Journal:  J Gastrointest Surg       Date:  2013-10-04       Impact factor: 3.452

3.  Deep sequencing and in silico analyses identify MYB-regulated gene networks and signaling pathways in pancreatic cancer.

Authors:  Shafquat Azim; Haseeb Zubair; Sanjeev K Srivastava; Arun Bhardwaj; Asif Zubair; Aamir Ahmad; Seema Singh; Moh'd Khushman; Ajay P Singh
Journal:  Sci Rep       Date:  2016-06-29       Impact factor: 4.379

4.  Loss of tumor suppressor Merlin results in aberrant activation of Wnt/β-catenin signaling in cancer.

Authors:  K Adam Morrow; Shamik Das; Erhong Meng; Mitchell E Menezes; Sarah K Bailey; Brandon J Metge; Donald J Buchsbaum; Rajeev S Samant; Lalita A Shevde
Journal:  Oncotarget       Date:  2016-04-05

Review 5.  Human osteopontin: Potential clinical applications in cancer (Review).

Authors:  Chengcheng Hao; Yuxin Cui; Sionen Owen; Wenbin Li; Shan Cheng; Wen G Jiang
Journal:  Int J Mol Med       Date:  2017-04-21       Impact factor: 4.101

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.